June 2022 in “Frontiers in Immunology” Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.
June 2024 in “International Journal of Dermatology” Upadacitinib may effectively treat resistant lichen planopilaris.
13 citations
,
February 2017 in “Clinical rheumatology” Tofacitinib may help treat nail dystrophy, especially when other treatments fail.
139 citations
,
November 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
December 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” Papulopustular rosacea is an inflammatory skin condition treatable with lifestyle changes and medications.
8 citations
,
July 2024 in “Children” Biologics and targeted therapies could improve treatment for children with certain chronic skin conditions.
2 citations
,
December 2018 in “Journal of cosmetic dermatology” Higher CRBP1 levels are linked to more severe alopecia areata.
4 citations
,
November 2021 in “Journal of Cosmetic Dermatology” QR678 and QR678 Neo treatments, combined with corticosteroid injections, work better for alopecia areata than corticosteroid injections alone.
9 citations
,
July 2016 in “JAAD case reports” Denosumab treatment for osteoporosis can cause hair loss.
January 2019 in “Actas urológicas españolas” Using mirabegron and solifenacin together is safe and more effective for treating overactive bladder than using either drug alone.
June 2026 in “Frontiers in Nutrition” The document discusses the use of GLP-1 receptor agonists (GLP-1RAs) in managing Polycystic Ovary Syndrome (PCOS), focusing on their metabolic benefits rather than confirmed fertility enhancement. The narrative synthesis highlights the need for individualized treatment plans, emphasizing the distinction between metabolic optimization and reproductive outcomes. The study suggests GLP-1RAs should be used as short-term, preconception tools, with careful planning for drug discontinuation to avoid rebound effects. The authors call for future trials to standardize reproductive endpoints and capture periconception exposure to better assess the benefits and risks.
March 2026 in “The American Journal of Managed Care” JAK inhibitors can help treat alopecia areata but have risks and high costs.
January 2024 in “International Journal of Molecular Sciences” Blocking the protein CXCL12 with a specific antibody can increase hair growth in common hair loss conditions.
Secukinumab treatment may cause HBV reactivation and hair discoloration.
August 2025 in “JAAD International” Bicalutamide may reduce hair shedding in women but needs longer trials to confirm its effectiveness.
15 citations
,
January 2024 in “The AAPS Journal” 50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.
1 citations
,
August 2019 in “Australasian journal of dermatology” Immunotherapy can help treat severe alopecia areata.
January 2026 in “Microorganisms” Bifidobacterium animalis subsp. lactis J12 helps reduce atopic dermatitis symptoms.
1 citations
,
August 2025 in “Australasian Journal of Dermatology” Anti-TNF therapy can cause a rare hair loss condition similar to alopecia areata.
March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
June 2020 in “Journal of Investigative Dermatology” Getting insurance to cover the hair loss treatment tofacitinib is hard because it's not officially approved for that use.
Baricitinib effectively regrows hair in severe alopecia areata cases.
December 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deucravacitinib helped a man regrow hair significantly.
February 2025 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deucravacitinib helped a man regrow hair and improve psoriasis.
May 2020 in “JAAD case reports” Using anthralin and calcipotriene together might help treat tough cases of alopecia areata, but more research is needed to understand how it works.
May 2026 in “Journal of Human Immunity” Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.
Thoracic medial branch block may be a simpler and effective alternative to thoracic vertebroplasty for pain management.
November 2025 in “Mendeley Data” Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.
7 citations
,
March 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” 97 citations
,
December 2011 in “New England Journal of Medicine” The FDA did not approve certain drugs for prostate cancer prevention due to concerns about their effectiveness and potential risks.